Bu-Hui Liu
Overview
Explore the profile of Bu-Hui Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
137
Followers
0
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu B, Chong F, Yuan C, Liu Y, Yang H, Wang W, et al.
Front Pharmacol
. 2024 Aug;
15:1446609.
PMID: 39108753
[This corrects the article DOI: 10.3389/fphar.2020.586725.].
2.
Wang M, Wang J, Cao D, Tu Y, Liu B, Yuan C, et al.
Front Pharmacol
. 2022 Apr;
13:790937.
PMID: 35370636
Fucoidan (FPS) has been widely used to treat renal fibrosis (RF) in patients with diabetic kidney disease (DKD); however, the precise therapeutic mechanisms remain unclear. Recently, research focusing on inflammation-derived...
3.
Wang M, Yue L, Wan Y, Huang H, Wu W, Tu Y, et al.
Zhongguo Zhong Yao Za Zhi
. 2021 Sep;
46(17):4471-4479.
PMID: 34581052
This study explored the in vivo effects and mechanisms of the modern classical prescription Supplemented Gegen Qinlian Decoction Formula(SGDF) against diabetic kidney disease(DKD). Sixty rats were randomly divided into the...
4.
Wang W, Liu Y, Wang M, Li H, Liu B, Tu Y, et al.
Front Pharmacol
. 2021 Aug;
12:662706.
PMID: 34408650
The proximal renal tubule plays a critical role in diabetic kidney disease (DKD) progression. Early glomerular disease in DKD triggers a cascade of injuries resulting in renal tubulointerstitial disease. These...
5.
Liu B, Tu Y, Ni G, Yan J, Yue L, Li Z, et al.
Front Pharmacol
. 2021 Aug;
12:667644.
PMID: 34335245
The total flavones of (TFA), a compound that is extracted from , has been widely used in China to reduce podocyte injury in diabetic kidney disease (DKD). However, the mechanisms...
6.
Liu B, Chong F, Yuan C, Liu Y, Yang H, Wang W, et al.
Front Pharmacol
. 2021 Mar;
11:586725.
PMID: 33708111
Recently, chronic kidney disease (CKD)-mineral and bone disorder (MBD) has become one of common complications occurring in CKD patients. Therefore, development of a new treatment for CKD-MBD is very important...
7.
Fang Q, Liu J, Wan Y, Liu B, Tu Y, Wu W, et al.
Zhongguo Zhong Yao Za Zhi
. 2021 Jan;
45(24):6003-6011.
PMID: 33496141
Fucoidan(FPS) is an effective component of the Chinese patent medicine named Haikun Shenxi, which treats schronic renal failure in clinics, and has the potential anti-aging effects. However, it is still...
8.
Wu W, Liu Y, Wan Y, Cao D, Fang Q, Tu Y, et al.
Zhongguo Zhong Yao Za Zhi
. 2021 Jan;
45(23):5797-5803.
PMID: 33496121
To observe the multi-targeted therapeutic effects of Huangkui Capsules(HKC)on insulin resistance(IR)and urine microalbumin in the early diabetic kidney disease(DKD)patients. The case data from the 83 DKD patients at G2 and...
9.
Tu Y, Fang Q, Sun W, Liu B, Liu Y, Wu W, et al.
Front Pharmacol
. 2020 Oct;
11:566611.
PMID: 33101025
Background: Recently, progression of chronic renal failure (CRF) has been closely associated with gut microbiota dysbiosis and intestinal metabolite-derived microinflammation. In China, total flavones of (TFA), a component of ,...
10.
Wang W, Han W, Wan Y, Tu Y, Liu B, Liu Y, et al.
Zhongguo Zhong Yao Za Zhi
. 2020 Apr;
45(1):7-13.
PMID: 32237405
The progression of renal damage in diabetic nephropathy(DN)is closely related to Nod-like receptor protein3(NLRP3)inflammasome activation. The characteristics of NLRP3 inflammasome activation include the changed expression and combination levels of NLRP3,...